Literature DB >> 16934043

Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

Dean Patterson1, Gordon T McInnes, John Webster, Malcolm M Mitchell, Thomas M Macdonald.   

Abstract

AIMS: To test the non-inferiority of a single dose of tadalafil 20 mg compared with placebo with respect to 26-h mean ambulatory systolic and diastolic blood pressure in treated and untreated hypertensive subjects.
METHODS: A multicentre, randomized, double-blind, placebo-controlled crossover study in 114 subjects with hypertension (36 subjects on no therapy with daytime mean ambulatory blood pressure >/= 140/85 mmHg; 38 subjects on two to four classes of antihypertensive agents with daytime mean ambulatory blood pressure >/=140/85 mmHg and 40 subjects on two to four classes of antihypertensive agents with ambulatory blood pressure < 140/85 mmHg).
RESULTS: Overall tadalafil reduced mean ambulatory blood pressure monitor systolic and diastolic blood pressure by 4.8 mmHg [95% confidence interval (Cl) 3.7, 5.9; P < 0.01] and 2.9 mmHg (95% CI 1.9, 3.6; P < 0.01), respectively, compared with placebo. In hypertensive subjects with uncontrolled blood pressure on two to four classes of antihypertensive agents (n = 36) tadalafil reduced mean ABPM systolic and diastolic blood pressure by 7.5 mmHg (95% CI 5.4, 9.6; P < 0.01) and 4.3 mmHg (95% CI 6.1, 8.9; P < 0.01) compared with placebo.
CONCLUSIONS: In patients with uncontrolled hypertension on multiple agents the addition of tadalafil 20 mg lowered mean 26-h blood pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934043      PMCID: PMC1885145          DOI: 10.1111/j.1365-2125.2006.02658.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences.

Authors:  I A Ayta; J B McKinlay; R J Krane
Journal:  BJU Int       Date:  1999-07       Impact factor: 5.588

2.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

3.  Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy.

Authors:  R A Kloner; R Sadovsky; E G Johnson; D Mo; S Ahuja
Journal:  Int J Impot Res       Date:  2005 Sep-Oct       Impact factor: 2.896

4.  An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.

Authors:  Vincenzo Mirone; Pierre Costa; Jan-Erik Damber; Simon Holmes; Ignacio Moncada; Hermann Van Ahlen; Eric Wespes; William H Cordell; Melanie Chan; Danilo Lembo; Lucio Varanese
Journal:  Eur Urol       Date:  2005-03-09       Impact factor: 20.096

5.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

Authors:  R M Wallis; J D Corbin; S H Francis; P Ellis
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

6.  A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men.

Authors:  C G McMahon; B G A Stuckey; D W Lording; G A Wittert; A Murphy; J Shin; P D Sutherland; N R Palmer; M P Lowy; D R Jesudason; P Fredlund
Journal:  Int J Clin Pract       Date:  2005-02       Impact factor: 2.503

7.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.

Authors:  H A Feldman; I Goldstein; D G Hatzichristou; R J Krane; J B McKinlay
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

8.  British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.

Authors:  Bryan Williams; Neil R Poulter; Morris J Brown; Mark Davis; Gordon T McInnes; John F Potter; Peter S Sever; Simon McG Thom
Journal:  BMJ       Date:  2004-03-13

9.  Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.

Authors:  F Montorsi; B Verheyden; E Meuleman; K-P Jünemann; I Moncada; L Valiquette; A Casabé; C Pacheco; J Denne; J Knight; S Segal; V S Watkins
Journal:  Eur Urol       Date:  2004-03       Impact factor: 20.096

10.  Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

Authors:  Robert A Kloner; Graham Jackson; Jeffrey T Emmick; Malcolm I Mitchell; Alun Bedding; Margaret R Warner; Alvaro Pereira
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

View more
  4 in total

1.  Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial.

Authors:  Bradley A Maron; Gaurav Choudhary; Rebekah L Goldstein; Eric Garshick; Matthew Jankowich; Troo J S Tucker; Kathleen A LaCerda; Brack Hattler; Edward C Dempsey; Ruxana T Sadikot; Shelley Shapiro; Sharon I Rounds; Ronald H Goldstein
Journal:  Pulm Circ       Date:  2022-03-14       Impact factor: 2.886

2.  The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.

Authors:  Ajay Nehra; Graham Jackson; Martin Miner; Kevin L Billups; Arthur L Burnett; Jacques Buvat; Culley C Carson; Glenn R Cunningham; Peter Ganz; Irwin Goldstein; Andre T Guay; Geoff Hackett; Robert A Kloner; John Kostis; Piero Montorsi; Melinda Ramsey; Raymond Rosen; Richard Sadovsky; Allen D Seftel; Ridwan Shabsigh; Charalambos Vlachopoulos; Frederick C W Wu
Journal:  Mayo Clin Proc       Date:  2012-08       Impact factor: 7.616

3.  Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications.

Authors:  Robert A Kloner; John B Kostis; Thomas P McGraw; Chunfu Qiu; Alankar Gupta
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-01-31       Impact factor: 2.885

4.  Tadalafil in patients on antihypertensive medications: Does safety remain an issue?

Authors:  Panagiotis Theofilis; Nikos Nakas; Rigas G Kalaitzidis
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-01-31       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.